| Aug 7 |
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 5 |
Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|
| Aug 1 |
Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
|
| Aug 1 |
Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors
|
| Jul 25 |
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2024 Financial Results and Pipeline Update
|
| Jul 9 |
Taiho exercises option for Arcus Biosciences’ quemliclustat in Asia
|
| Jul 8 |
Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia
|
| Jul 8 |
Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences
|
| Jun 10 |
Arcus Completes Enrollment in Phase 3 Trial of Domvanalimab-Containing Regimen for Stomach Cancer
|
| Jun 10 |
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
|
